Back to search
FDAFDA · Food and drugs·Recall number D-0526-2023

Tadalafil Tablets, USP, 20 mg, 7-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-8153-7

Published April 12, 2023 · Recall initiated: March 23, 2023

Summary

FDA records drug Class II recall D-0526-2023, published April 12, 2023 and initiated March 23, 2023. Recalling firm: Preferred Pharmaceuticals, Inc.; Status: Ongoing; Reported quantity: 32 Bottles; Lot: Lot: C0822E, Exp 1/31/2024, F1121B, Exp 1/31/2024, G2721L, Exp 1/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

What to do

Voluntary: Firm initiated · Letter

Get an email if TADALAFIL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TADALAFIL
Manufacturer
Preferred Pharmaceuticals, Inc.
Distributor
USA Nationwide
Lot
Lot: C0822E, Exp 1/31/2024, F1121B, Exp 1/31/2024, G2721L, Exp 1/31/2024.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tadalafil Tablets, USP, 20 mg, 7-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-8153-7 recalled?

Yes. FDA published recall D-0526-2023 on April 12, 2023. Reported hazard: cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TADALAFIL.